Read this company snapshot
Daily valuation snapshot
Recursion Pharmaceuticals, Inc. Class A Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $4.36
- Market capitalization (USD)
- $2,334,091,861.2
- Price / earnings (TTM)
- Not reported
- Price / book
- 2.55
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research RXRX in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research RXRX in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing RXRX with another company.
| Daily close (USD) | $4.36 |
| Market capitalization (USD) | $2,334,091,861.2 |
| Price / earnings (TTM) | Not reported |
| Price / book | 2.55 |
No matching rows. Clear the filter to see all records.
Read RXRX's valuation metrics
Company size
Recursion Pharmaceuticals, Inc. Class A Common Stock's recorded market capitalization is $2,334,091,861.2. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
RXRX's recorded price-to-book ratio is 2.55. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Recursion Pharmaceuticals, Inc. Class A Common Stock with Aurora
Use the snapshot above to ask a specific question about RXRX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow RXRX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.